DIM Sartorius Stedim Biotech SA

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

Sartorius Stedim Biotech SA / Key word(s): Dividend/AGM/EGM
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

07-Feb-2024 / 17:30 CET/CEST

Aubagne, February 7, 2024

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023. Under this proposal, the total distributed profit would be 67.1 million euros. The dividend will be paid on April 4, 2024.

The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2023 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024.

This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.


Financial calendar
February 16, 2024        Publication of the 2023 Annual Report
March 26, 2024            Annual General Meeting
April 18, 2024               Publication of the quarterly figures January to March 2024
July 19, 2024                Publication of the half-year figures January to June 2024
October 17, 2024          Publication of the nine-month figures January to September 2024


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 10,600 employees are working for customers around the globe.


Contact
Timo Lindemann
External Communications
+49 (0)551.308.4724
Attachment

File:

Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:
E-mail:
Internet: -stedim.com
ISIN: FR0013154002
EQS News ID: 1832769

 
End of Announcement - EQS News Service

1832769  07-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1832769&application_name=news&site_id=research_pool
EN
07/02/2024

Underlying

DIMSartorius Stedim Biotech SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius Stedim Biotech SA

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
EUR 4645.50
DIM Sartorius Stedi...

Sartorius Stedim - More Downside to Come (SELL, TP EUR150 [165], 9 pgs...

The capitulation may be upon us. The order book continues to show weakness & contrary to the befuddling Q423 sales strength, equipment sales look likely to stay weak as CDMO’s reduce CAPEX after 3yrs of turbo charged growth. We now question the trend growth rate as we believe that market share gains will be minimal, CDMO CAPEX will recover very slowly & M&A is unlikely to contribute as much as it did in the past. Moreover, we expect DIM to add significant capacity in the coming 24mths, which is ...

DIM SARTORIUS STEDIM BIOTECH SA
04/19/24 April 19, 2024 1 EN
Maissa Keskes ... (+2)
  • Maissa Keskes
  • Stephane Houri
FP TOTAL SE
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
04/18/24 April 18, 2024 1 EN
Maissa Keskes ... (+2)
  • Maissa Keskes
  • Stephane Houri
FP TOTAL SE
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
04/18/24 April 18, 2024 1 FR
Oliver Metzger
  • Oliver Metzger
DIM Sartorius Stedi...

Sartorius Stedim Biotech : Q1 review -Some stabilisation, but sales an...

>Q1 with some stabilisation – sales and order intake weaker than expected - Q1 2024 revenues of € 667m (-8.1% y-o-y,-2%/-4% vs ODDO BHF/consensus) were impacted by an organic decline of 9.4%. The decline in constant currencies was at -6.7%. Sartorius Stedim Biotech was impacted by mixed dynamics across its portfolio and regions. Demand continued to normalise the consumables business with positive order momentum, which indicates further progress in destocking. Simultan...

DIM SARTORIUS STEDIM BIOTECH SA
04/18/24 April 18, 2024 1 EN
 PRESS RELEASE
Free
DIM Sartorius Stedi...

Sartorius Stedim Biotech publishes unaudited first quarter results for...

Sartorius Stedim Biotech SA / Key word(s): Quarter Results Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST   Aubagne, France | April 18, 2024 Sartorius Stedim Biotech publishes unaudited first quarter results for 2024   Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent) Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains we...

April 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch